Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity.

Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Abstract Text:

    anthony t powerAnthony T Power,jiahu wangJiahu Wang,theresa j fallsTheresa J Falls,jennifer m patersonJennifer M Paterson,kelley a paratoKelley A Parato,brian d lichtyBrian D Lichty,david f stojdlDavid F Stojdl,peter a j forsythPeter A J Forsyth,harry atkinsHarry Atkins,john c bellJohn C Bell,anthony t powerAnthony T Power,jiahu wangJiahu Wang,theresa j fallsTheresa J Falls,jennifer m patersonJennifer M Paterson,kelley a paratoKelley A Parato,brian d lichtyBrian D Lichty,david f stojdlDavid F Stojdl,peter a j forsythPeter A J Forsyth,harry atkinsHarry Atkins,john c bellJohn C Bell,

    Oncolytic viruses capable of tumor-selective replication and cytolysis have shown early promise as cancer therapeutics. However, the host immune system remains a significant obstacle to effective systemic administration of virus in a clinical setting. Here, we demonstrate the severe negative impact of the adaptive immune response on the systemic delivery of oncolytic vesicular stomatitis virus (VSV) in an immune-competent murine tumor model, an effect mediated primarily by the neutralization of injected virions by circulating antibodies. We show that this obstacle can be overcome by administering virus within carrier cells that conceal viral antigen during delivery. Infected cells were delivered to tumor beds and released virus to infect malignant cells while sparing normal tissues. Repeated administration of VSV in carrier cells to animals bearing metastatic tumors greatly improved therapeutic efficacy when compared with naked virion injection. Whole-body molecular imaging revealed that carrier cells derived from solid tumors accumulate primarily in the lungs following intravenous injection, whereas leukemic carriers disseminate extensively throughout the body. Furthermore, xenogeneic cells were equally effective at delivering virus as syngeneic cells. These findings emphasize the importance of establishing cell-based delivery platforms in order to maximize the efficacy of oncolytic therapeutics.Molecular Therapy (2007) 15, 123-130. doi:10.1038/sj.mt.6300039.

    Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Publishing Authors By Initials

    at powerAT Power,j wangJ Wang,tj fallsTJ Falls,jm patersonJM Paterson,ka paratoKA Parato,bd lichtyBD Lichty,df stojdlDF Stojdl,pa forsythPA Forsyth,h atkinsH Atkins,jc bellJC Bell,at powerAT Power,j wangJ Wang,tj fallsTJ Falls,jm patersonJM Paterson,ka paratoKA Parato,bd lichtyBD Lichty,df stojdlDF Stojdl,pa forsythPA Forsyth,h atkinsH Atkins,jc bellJC Bell,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Molecular therapy : the journal of the American So

    VOLUME: 15

    Page Numbers: 123-30

    Journal Abbreviation: Mol. Ther.

    ISSN: 1525-0016

    DAY: 13

    MONTH: Jan

    YEAR: 2007

    Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 100890581

    Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity.

    AFFILIATION: 1Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa Health Research Institute, Centre for Cancer Therapeutics, Ottawa, Ontario, Canada.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Mol Ther

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News